Acumen sinks after Alzheimer's drug fails mid-stage study

JCR Pharmaceuticals

30/10/2026 13:11

Updates
** Shares of Acumen Pharmaceuticals ABOS.O plunge 85% to $0.34 premarket
** The biotech firm says its experimental intravenous Alzheimer's disease drug sabirnetug failed the main goal of a mid-stage study, showing no meaningful benefit in slowing memory and functional decline versus placebo
** Co says key secondary measures, including CDR-SB, also failed to reach statistical significance
** Drug reduced amyloid plaque levels in the brain, but that did not translate into clinical benefit
** ABOS's pipeline includes a subcutaenous version of sabirnetug in early-stage testing and a preclinical enhanced brain delivery program in collaboration with Japan's JCR Pharmaceuticals 4552.T
** Co plans to stop development of sabirnetug, end the study's extension phase and implement cash-conservation measures
** As of last close, stock up ~9% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))